Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 2/20 | 0.41 |
| ▸ | PIM1 | P11309 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | GNAI3 | P08754 | 2/20 | 0.33 |
| ▸ | GNAO1 | P09471 | 2/20 | 0.33 |
| ▸ | GNAI1 | P63096 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.30 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.30 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.30 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13503179 | 1.00 | EPHX1 (0.41) | EPHX1PIM1KCNH2GAAL3MBTL1 | |
| SCHEMBL23365995 | 0.95 | GAA (0.36) | EPHX1PIM1GAAL3MBTL1 | |
| SCHEMBL2106218 | 0.93 | EPHX1 (0.41) | EPHX1KCNH2GAAL3MBTL1GNAI3 | |
| Hydrochloric Acid SCHEMBL6016942 | 0.91 | GNAI3 (0.39) | EPHX1KCNH2GAAL3MBTL1GNAI3 | |
| Hydrochloric Acid SCHEMBL3413064 | 0.91 | GNAI3 (0.39) | EPHX1KCNH2GAAL3MBTL1GNAI3 | |
| Bicarbonate SCHEMBL3920858 | 0.83 | EPHX1 (0.48) | EPHX1GAAL3MBTL1GNAI3GNAO1 | |
| SCHEMBL7327965 | 0.82 | KCNH2 (0.39) | KCNH2KDM1A | |
| SCHEMBL15016647 | 0.82 | KCNH2 (0.39) | KCNH2KDM1A | |
| SCHEMBL12258977 | 0.82 | KCNH2 (0.39) | KCNH2KDM1A | |
| SCHEMBL3980551 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10414763-B2 | Azaquinazoline inhibitors of atypical protein kinase C | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2019-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10414763-B2 | Azaquinazoline inhibitors of atypical protein kinase C | PRKCQ, PRKCA, PRKCZ | EPHX1 4049/4885PIM1 619/4885KCNH2 1301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.